See more : NAGAWA Co., Ltd. (9663.T) Income Statement Analysis – Financial Results
Complete financial analysis of Ampio Pharmaceuticals, Inc. (AMPE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ampio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- archTIS Limited (AR9.AX) Income Statement Analysis – Financial Results
- High Tide Resources Corp. (HTRC.CN) Income Statement Analysis – Financial Results
- RSC International Limited (RSCINT.BO) Income Statement Analysis – Financial Results
- bowmo, Inc. (BOMOD) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMAT) Income Statement Analysis – Financial Results
Ampio Pharmaceuticals, Inc. (AMPE)
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 76.79K | 50.00K | 50.00K | 18.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 250.00K | 2.08M | 1.09M | 1.18M | 1.27M | 523.00K | 568.00K | 950.00K | 369.31K | 2.24M | 1.74M | 1.45M | 0.00 | 0.00 | 0.00 | 950.00 | 0.00 | 0.00 |
| Gross Profit | -250.00K | -2.08M | -1.09M | -1.18M | -1.27M | -523.00K | -568.00K | -950.00K | 793.15K | -2.16M | -1.69M | -1.40M | 18.75K | 0.00 | 0.00 | -950.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 68.23% | -2,818.46% | -3,376.00% | -2,798.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.44M | 8.92M | 11.90M | 9.17M | 12.62M | 6.83M | 10.42M | 10.55M | 18.96M | 26.92M | 18.29M | 7.49M | 6.65M | 1.97M | 1.07M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Other Expenses | 0.00 | 1.94M | 0.00 | 12.00K | 56.00K | 0.00 | 323.55K | 143.80K | 0.00 | 0.00 | 0.00 | 0.00 | 34.01K | 0.00 | 0.00 | 950.00 | 1.20K | 0.00 |
| Operating Expenses | 9.27M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.10M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Cost & Expenses | 9.52M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.46M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Interest Income | 348.00K | 220.00K | 4.00K | 12.00K | 77.00K | 5.00K | 3.09K | 23.48K | 59.85K | 22.26K | 12.29K | 21.94K | 6.68K | 815.00 | 1.09K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.36K | 19.55K | 4.18K | 2.65K | 0.00 | 0.00 |
| Depreciation & Amortization | 127.00K | 2.08M | 1.09M | 1.18M | 1.27M | 1.28M | 1.21M | 1.21M | 1.14M | 439.10K | 137.68K | 62.40K | 42.55K | 815.00 | 0.00 | 0.00 | 2.19K | 0.00 |
| EBITDA | 0.00 | -18.30M | 0.00 | 0.00 | -17.30M | 35.26M | -14.46M | -14.81M | -23.34M | 0.00 | -23.89M | -11.76M | -11.08M | -8.01M | -21.87K | -29.23K | -26.81K | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,760.35% | -50,310.73% | -47,747.81% | -23,472.97% | -59,119.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.52M | -24.21M | -25.16M | -15.22M | -23.45M | -11.18M | -15.56M | -17.08M | -33.30M | -39.07M | -24.02M | -11.82M | -11.13M | -6.70M | -21.87K | -29.23K | -29.00K | -1.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,864.79% | -50,882.57% | -48,047.74% | -23,641.65% | -59,382.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 886.00K | 4.05M | 3.50M | -60.00K | 4.95M | 45.17M | -36.22M | -2.08M | -412.07K | -7.60M | -504.16K | 227.29K | -7.14M | -1.35M | -4.18K | -2.65K | -2.19K | 0.00 |
| Income Before Tax | -8.63M | -16.34M | -17.08M | -15.89M | -13.63M | 33.99M | -51.89M | -19.16M | -33.71M | -39.05M | -24.53M | -11.59M | -18.28M | -8.05M | -26.05K | -31.88K | -31.20K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,900.24% | -50,853.58% | -49,056.85% | -23,186.23% | -97,475.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.87M | -4.59M | 604.00K | -4.95M | 45.17M | 36.33M | 1.04M | -1.29M | -923.52K | -519.87K | -68.00 | 82.50K | 18.73K | 0.00 | 0.00 | 800.00 | 1.00K |
| Net Income | -8.63M | -8.47M | -12.49M | -16.50M | -8.68M | 33.99M | -51.89M | -19.16M | -32.01M | -38.13M | -24.01M | -11.59M | -18.36M | -8.05M | -26.05K | -31.88K | -32.00K | -1.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,753.66% | -49,650.87% | -48,017.12% | -23,186.09% | -97,915.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -10.67 | -11.24 | -18.79 | -28.63 | -18.32 | 92.10 | -239.13 | -107.06 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| EPS Diluted | -10.66 | -11.24 | -18.59 | -27.71 | -18.32 | 91.90 | -238.41 | -106.91 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| Weighted Avg Shares Out | 809.00K | 753.62K | 664.33K | 576.16K | 474.03K | 369.00K | 217.00K | 179.00K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
| Weighted Avg Shares Out (Dil) | 810.11K | 753.62K | 671.49K | 595.41K | 474.03K | 369.81K | 217.66K | 179.24K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
Hot Penny Stocks to Buy? 3 to Watch As Vaccine Rates Hit New Highs
Best penny stocks to watch with vaccine rates higher than ever The post Hot Penny Stocks to Buy? 3 to Watch As Vaccine Rates Hit New Highs appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India
ENGLEWOOD, Colo., June 15, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it has received regulatory approval to expand enrollment of its AP-019 Phase II...
Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo
ENGLEWOOD, Colo., June 14, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's poster presentation, "Pivoting From One to Multiple...
Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium
ENGLEWOOD, Colo., June 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that management will participate in a series of one-on-one meetings with...
Ampio Pharmaceuticals: Regulatory Process Taking Too Long
Ampio has existed for over a decade, and run more than a dozen trials for lead asset Ampion. Regulatory path is still unclear for osteoarthritis of the knee.
Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress
ENGLEWOOD, Colo., May 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the company's poster presentation, "Regulatory Decisions during COVID-19: Efficient...
Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)
ENGLEWOOD, Colo., May 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational...
Ampio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q1 2021 Results - Earnings Call Transcript
Ampio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q1 2021 Results - Earnings Call Transcript
Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
ENGLEWOOD, Colo., May 5, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today reported quarterly financial results for the...
Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%
ENGLEWOOD, Colo., April 27, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today revealed positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in...
Source: https://incomestatements.info
Category: Stock Reports